Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir - Wikidata - wikimedia - TriplyDB

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

http://www.wikidata.org/entity/Q28748931

about

sameAs

Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance Unveiling the roles of HBV polymerase for new antiviral strategies Extensive mutagenesis of the conserved box E motif in duck hepatitis B virus P protein reveals multiple functions in replication and a common structure with the primer grip in HIV-1 reverse transcriptase Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.Lead identification for the K-Ras protein: virtual screening and combinatorial fragment-based approaches Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.Regioselective Synthesis of Pyrazolo[3,4-D]Pyrimidine Based Carbocyclic Nucleosides as Possible Antiviral Agent.Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy.

P2860

Q27013849-A1F72F52-0233-4D9E-B47C-646A034F5048 Q28542705-FCB6D0BA-AFD6-4132-801D-2186E9306A06 Q28547647-9CCB38F5-D97D-4823-88BA-CCD7A22DC60C Q35441503-A3C6DE52-1117-4842-B660-D961115B8117 Q36086762-0EB105F6-C88A-4B78-B9A9-E0CA1FBD5F96 Q36120901-89653C5E-9B66-4B22-981F-F934F87E90EF Q36883272-68C4968F-7A45-4C86-BF50-0249BA11E024 Q37964712-5EF3B2A9-C7F7-4704-BD43-89D7E18CD3FE Q40951420-10C2ADBF-DFF6-46EA-A245-BC67FF13BD39 Q42148791-0CA36DC8-0D2C-4883-B471-8E4EC0B7916C

P2860

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

http://www.wikidata.org/entity/Q28748931

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Mechanistic characterization a ...... merase resistance to entecavir

@ast

Mechanistic characterization a ...... merase resistance to entecavir

@en

Mechanistic characterization a ...... merase resistance to entecavir

@nl

type

label

Mechanistic characterization a ...... merase resistance to entecavir

@ast

Mechanistic characterization a ...... merase resistance to entecavir

@en

Mechanistic characterization a ...... merase resistance to entecavir

@nl

prefLabel

Mechanistic characterization a ...... merase resistance to entecavir

@ast

Mechanistic characterization a ...... merase resistance to entecavir

@en

Mechanistic characterization a ...... merase resistance to entecavir

@nl

P1433

Q28748931-6C6F53D9-67CF-47E3-BB29-DAB48E2891B3

P1476

Q28748931-B78DF615-D91D-4925-B526-18FE2852CB35

P2093

Q28748931-C6B02D66-5E00-426D-81ED-01C4C6F5096C

Q28748931-F36732A9-101F-4BA8-B8E9-68C16F3F2B0B

Q28748931-FD6045E7-73E9-468B-A8D3-4414D9FAB887

Q28748931-FF496EA9-0545-4F97-B2A9-E86E026A2CAE

P2860

Q28748931-01FC9E17-5CB5-4BFF-887B-57E1701F4ADE

Q28748931-241A6E0D-8E7D-449E-98CD-C208A3C33FD8

Q28748931-29F7BC4A-AD83-40A5-BDEF-74150AA95753

Q28748931-2DDF5F7B-6D4C-4263-84C8-07F8C8959C9E

Q28748931-2F3F51FF-7928-4C8B-A152-E924FFB4E63D

Q28748931-4410E48D-A52C-4A05-863D-C26E56BA4C72

Q28748931-4702D0E0-7CDE-4FE1-A202-81F17A34019A

Q28748931-5DD73E6A-D424-4217-9B1A-FB115E695B81

Q28748931-61AF1A87-7C4C-45E0-AFE5-084960C9AA9A

Q28748931-64A40667-457D-4BC4-A247-EF7BFD765AEF

P304

Q28748931-A816B2BF-4793-45BC-B3FA-F9CD56A3DD12

P31

Q28748931-6C969E46-BC65-46AB-B49E-1CDA072DBC31

P3181

Q28748931-63C3E233-8457-4F59-AAB6-EA996B968D59

P356

Q28748931-1D15F740-86A3-45A0-B07D-6E2CC43B9A6C

P407

Q28748931-AE9AEAF1-3039-42A1-8D5F-BC7EE63402AC

P433

Q28748931-5623BB0A-A9F6-45AA-96A7-0E113681492A

P478

Q28748931-780E9EBD-969C-49B9-BEE0-8168B1470B74

P577

Q28748931-F87D731B-92F4-4021-B343-E8576B3A4887

P5875

Q28748931-3B09F48E-B828-4367-8A01-8C528437FF61

P698

Q28748931-41FDCD54-34CE-4143-9EFE-2656882F9FD6

P932

Q28748931-FACEEF98-89A2-49F9-A3EC-A7D70EDB8258

P3181

P356

JOURNAL.PONE.0009195

P1433

P1476

Mechanistic characterization a ...... merase resistance to entecavir

@en

P2093

Ann W Walsh

http://www.w3.org/2001/XMLSchema#string

Daniel J Tenney

http://www.w3.org/2001/XMLSchema#string

David R Langley

http://www.w3.org/2001/XMLSchema#string

Richard J Colonno

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

All-atom empirical potential for molecular modeling and dynamics studies of proteins

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

P304

e9195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1910376

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0009195

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41487832

http://www.w3.org/2001/XMLSchema#string

P698

20169198

http://www.w3.org/2001/XMLSchema#string

P932

2820545

http://www.w3.org/2001/XMLSchema#string